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The World Health Organization inﬂuenza forecast now includes an inﬂuenza B strain from
each  of the inﬂuenza B lineages (B/Yamagata and B/Victoria) for inclusion in seasonal
inﬂuenza vaccines. Traditional trivalent inﬂuenza vaccines include an inﬂuenza B strain
from one lineage, but because two inﬂuenza B lineages frequently co-circulate, the effec-
tiveness of trivalent vaccines may be reduced in seasons of inﬂuenza B vaccine-mismatch.
Thus, quadrivalent vaccines may potentially reduce the burden of inﬂuenza compared with
trivalent vaccines.
In this Phase III, open-label study, we assessed the immunogenicity and safety of Southern
Hemisphere inactivated quadrivalent inﬂuenza vaccine (FluarixTM Tetra) in Brazilian adults
(NCT02369341). The primary objective was to assess hemagglutination-inhibition antibody
responses against each vaccine strain 21 days after vaccination in adults (aged ≥18–60 years)
and  older adults (aged >60 years). Solicited adverse events for four days post-vaccination,
and unsolicited adverse events and serious adverse events for 21 days post-vaccination were
also assessed.
A total of 63 adults and 57 older adults received one dose of inactivated quadrivalentinﬂuenza vaccine at the beginning of the 2015 Southern Hemisphere inﬂuenza season.
 adults and older adults, the hemagglutination-inhibition titers ful-After vaccination, inPlease cite this article in press as: Zerbini CA, et al. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent inﬂuenza
vaccine: a Phase III, open-label study of adults in Brazil. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.10.003
ﬁlled the European licensure criteria for immunogenicity. In adults, the seroprotection
rates with HI titer ≥1:40 were 100% (A/H1N1), 98.4% (A/H3N2), 100% (B/Yamagata), and
100% (B/Victoria); in older adults were 94.7% (A/H1N1), 96.5% (A/H3N2), 100% (B/Yamagata),
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and 100% (B/Victoria). Pain was the most common solicited local adverse events in adults
(27/62) and in older adults (13/57), and the most common solicited general adverse events
in  adults was myalgia (9/62), and in older adults were myalgia and arthralgia (both 2/57).
Unsolicited adverse events were reported by 11/63 adults and 10/57 older adults.
The  study showed that inactivated quadrivalent inﬂuenza vaccine was immunogenic
and  well-tolerated in Brazilian adults and older adults.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/Introduction
Traditional trivalent inﬂuenza vaccines (inactivated trivalent
inﬂuenza vaccines [IIV3s] and live attenuated inﬂuenza vac-
cines [LAIV3s]) include two inﬂuenza A strains (A/H1N1 and
A/H3N2) and one inﬂuenza B strain that are recommended
annually for the Northern and Southern Hemispheres by the
World Health Organization (WHO) based on global surveillance.
However, in the early 1980s, two phylogenetically-distinct
inﬂuenza B lineages (B/Yamagata and B/Victoria) emerged
globally in humans.1 In a report published by The Global
Inﬂuenza B Study in 2015, it was estimated that based
on 26 countries in both Hemispheres and inter-tropical
regions between 2000 and 2013, the average rate of
inﬂuenza B lineage mismatch with the seasonal vaccine was
about 25%.2
Although data regarding the burden of inﬂuenza B in
Latin America are limited, inﬂuenza B has circulated in Brazil
during most seasons over the past decade and B lineage
has been reported in some seasons.3–7 Surveillance studies
between 2001 and 2013 show that one B lineage predomi-
nated in 10 seasons, and co-circulation was found in 2002,
2008, and 2013.5 During 2013, when the B/Victoria strain in
the Southern Hemisphere seasonal vaccine was mismatched,
the reported rate of inﬂuenza B mismatch with the vaccine
was >91% in Brazil, 100% in São Paulo, and 52% in South
America.3–6
In response to global reports of B lineage mismatch and
the hypothesis that quadrivalent vaccine may reduce the bur-
den of inﬂuenza disease compared with trivalent vaccine, for
the ﬁrst time in the 2012–2013 Northern Hemisphere inﬂuenza
season, the WHO  inﬂuenza forecast included an inﬂuenza
B strain from each of the inﬂuenza B lineages.8,9 By the
2014–2015 inﬂuenza season, various quadrivalent inﬂuenza
vaccines had been launched globally, and depending upon
the region and product, were licensed for use in adults and
children from 6 months of age.10–20
This Phase III, open-label study was conducted to assess
the immunogenicity and safety of Southern Hemisphere
inactivated quadrivalent inﬂuenza vaccine (IIV4) in adults in
Brazil.
MethodsPlease cite this article in press as: Zerbini CA, et al. Immunogenicity and
vaccine: a Phase III, open-label study of adults in Brazil. Braz J Infect Dis. 2
This Phase III, open-label study assessed the immunogenic-
ity and safety of IIV4 in adults (18–60 years) and older adults
(>60 years). The study was conducted in two centers in Brazillicenses/by-nc-nd/4.0/).
in 2015. Eligible subjects were aged ≥18 years, were in sta-
ble health, and had not received any non-registered drug or
vaccine within 30 days, or any investigational or approved
inﬂuenza vaccine within six months of the ﬁrst visit. All sub-
jects provided written informed consent.
The study protocol, informed consent and other infor-
mation requiring pre-approval were reviewed and approved
by Comissão Nacional de Ética em Pesquisa. The study was
conducted in accordance with Good Clinical Practice, the
principles of the Declaration of Helsinki, and all regulatory
requirements (NCT02369341).
Objectives
The primary objective was to assess vaccine immunogenicity
based on hemagglutination-inhibition (HI) antibody responses
against each vaccine strain 21 days after vaccination in adults
and older adults. Immunogenicity outcome measures (deﬁned
below) were assessed according to the European Commit-
tee for Medicinal Products for Human Use (CHMP) licensure
criteria for immunogenicity of inﬂuenza vaccines.21 The sec-
ondary immunogenicity objective was to assess HI antibody
responses in each age strata according to previous inﬂuenza
vaccine history during the preceding inﬂuenza season (2014)
and according to baseline serostatus.
Reactogenicity and safety were assessed as secondary
objectives and included solicited adverse events (AEs) (reacto-
genicity) for four days post-vaccination and unsolicited AEs,
serious AEs (SAEs) and medically-attended AEs (MAEs) for 21
days post-vaccination.
Vaccine
The inactivated split virion vaccine (FluarixTM Tetra) was a
thiomersal-free vaccine manufactured by GSK Vaccines in
Dresden, Germany. One 0.5 mL  dose contained 60 g hemag-
glutinin antigen (HA) including each of the four vaccine strains
recommended by WHO  for the 2015 inﬂuenza season in the
Southern Hemisphere: A/California/7/2009 (H1N1)pdm09-
like strain [variant A/Christchurch/16/2010 (NIB-74xp)],
A/Switzerland/9715293/2013 (H3N2)-like strain [variant
A/Switzerland/9715293/2013 (NIB-88)], B/Phuket/3073/2013-
like strain [B/Phuket/3073/2013] (Yamagata lineage),
B/Brisbane/60/2008-like strain [B/Brisbane/60/2008] (Victoria safety of Southern Hemisphere inactivated quadrivalent inﬂuenza
016. http://dx.doi.org/10.1016/j.bjid.2016.10.003
lineage).
Pre-ﬁlled syringes contained one dose of IIV4 which was
administered intramuscularly in the deltoid of the non-
dominant arm.
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Table 1 – Baseline characteristics in the total vaccinated
cohort.
Adults Older adults
18–60 years >60 years
N = 63 N = 57
Mean age, years (SD) 40.8 (12.2) 67.2 (6.0)
Median age, years (range) 41.0 (18–60) 66.0 (61–84)
Male, n (%) 11 (17.5) 19 (33.3)
Hispanic or Latino, n (%) 63 (100) 56 (98.2)
Vaccination history, n (%)
2014 (preceding season) 31 (49.2) 46 (80.7)
2013 29 (46.0) 48 (84.2)
2012 21 (33.3) 41 (71.9)
SD, standard deviation; N, number of subjects in group; n, numberb  r a z j i n f e c t d i s .
ssessments
mmunogenicity
lood samples were collected for immunogenicity assess-
ents before vaccination (Day 0) and 21 days (Day 21) after
accination. Antibody titers against the vaccine strains were
easured in serum samples using HI assays which were per-
ormed at a GSK Vaccines laboratory in Quebec, Canada using
tandardized procedures as previously described.22
Geometric mean titers (GMTs) were obtained by comput-
ng the anti-log of the arithmetic mean of the log transformed
nverse titers. Subjects with HI antibody titers ≥1:10 were
onsidered to be seropositive. HI antibody responses were
escribed as seroconversion rate (SCR, deﬁned as the percent-
ge of subjects who  had pre- and post-vaccination titers of
1:10 and ≥1:40, respectively, or a pre-vaccination titer of ≥1:10
nd ≥4-fold increase in post-vaccination titer), seroprotection
ate (SPR, deﬁned as the percentage of subjects with a post-
accination titer of ≥1:40), and the mean geometric increase
MGI, deﬁned as the geometric mean of the ratio between pre-
accination and post-vaccination reciprocal HI titers).
eactogenicity  and  safety
he occurrence, intensity, and duration of solicited AEs were
ecorded by subjects on diary cards for 4-days post vaccination
nd included injection site AEs (pain, redness, and swelling)
nd general AEs (arthralgia, fatigue, gastrointestinal symp-
oms, headache, generalized myalgia, shivering, and fever).
njection site reactions were considered to be related to vac-
ination and investigators provided causality assessments for
olicited general AEs. Solicited events were graded for sever-
ty using a standard three grade scale: Grade 1, ‘no effect
n normal activities’ (‘>20 to 50 mm’  for injection site red-
ess and swelling); Grade 2, ‘some interference with normal
veryday activities’ (‘>50 to 100 mm’  for injection site red-
ess and swelling); and Grade 3, ‘prevents normal everyday
ctivities’ (‘>100 mm’  for injection site redness and swelling).
ever was graded as: Grade 1 ≥38.0 to ≤38.5 ◦C, Grade 2 >38.5
o ≤39.0 ◦C, and Grade 3 >39.0 ◦C. Unsolicited AEs including
edically-attended events (MAEs) and serious adverse events
SAEs) were assessed for 21 days post-vaccination. Unsolicited
Es were coded using the Medical Dictionary for Regulatory
ctivities Preferred Terms. Investigators provided causality
ssessments for all unsolicited events.
tatistics
t least 50 evaluable subjects in each age strata (18–60 years
nd >60 years) were to be assessed for immunogenicity based
n regulatory requirements for the annual registration of
nﬂuenza vaccines (CPMP/BWP/214/96).21 Target enrolment
as 60 subjects, in each age strata.
The vaccine fulﬁlls the European CHMP licensure criteria
or immunogenicity if at least one criteria was met: point esti-
ate for SPR >70%, SCR >40%, and MGI  >2.5 (adults aged 18–60Please cite this article in press as: Zerbini CA, et al. Immunogenicity and
vaccine: a Phase III, open-label study of adults in Brazil. Braz J Infect Dis. 2
ears), or SPR >60%, SCR >30%, and MGI  >2.0 (older adults >60
ears).21 All immunogenicity outcomes were tabulated with
5% conﬁdence intervals (CIs). The immunogenicity analyses
ere performed on the per-protocol immunogenicity cohortof subjects with characteristic.
including all eligible subjects without protocol deviation who
had serological data available at Day 0 and Day 21.
Solicited and unsolicited AEs were tabulated with 95% CIs.
Reactogenicity and safety analyses were performed on all vac-
cinated subjects (total vaccinated cohort).
Results
The ﬁrst subject was enrolled on 29 April 2015 and all subjects
had completed the study by 3 June 2015.
A total of 121 subjects were enrolled, and 120 were vac-
cinated (total vaccinated cohort), including 63 adults and
57 older adults. The per-protocol immunogenicity cohort
included of a total of 119 subjects (62 adults and 57 older
adults) who completed the study. One subject in the adult
group withdrew from the study (moved from the study area).
The mean (range) age in the adult group was 40.8 years (18–60
years), and in the older adult group was 67.2 years (61–84 years)
(Table 1). Thirty-one of 63 adults and 46 of 57 older adults had
received inﬂuenza vaccination in the preceding season.
Immunogenicity
At baseline in the adult group, 82.3% and 83.9% of subjects
were seropositive for A/H1N1 and A/H3N2, respectively, and
the seropositivity rate for both B/Yamagata and B/Victoria was
95.2%. At baseline in the older adult group, the seropositivity
rate was 91.2% for both A/H1N1 and A/H3N2, and was 100% for
both B/Yamagata and B/Victoria. At Day 21 post-vaccination,
100% of adults and older adults were seropositive for all vac-
cine strains.
At Day 21 post-vaccination, GMTs in adults were 460.2
(A/H1N1), 338.4 (A/H3N2), 338.4 (B/Yamagata), and 365.9
(B/Victoria), and in older adults were 166.9 (A/H1N1), 306.7
(A/H3N2), 226.3 (B/Yamagata), and 288.6 (B/Victoria) (Fig. 1).
At Day 21 post-vaccination, the SCRs, SPRs, and MGIs
fulﬁlled the European CHMP licensure criteria for immuno-
genicity (Fig. 2). Point estimates for SPRs in adults were safety of Southern Hemisphere inactivated quadrivalent inﬂuenza
016. http://dx.doi.org/10.1016/j.bjid.2016.10.003
100% (A/H1N1), 98.4% (A/H3N2), 100% (B/Yamagata), and 100%
(B/Victoria), and in older adults were 94.7% (A/H1N1), 96.5%
(A/H3N2), 100% (B/Yamagata), and 100% (B/Victoria).
Please cite this article in press as: Zerbini CA, et al. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent inﬂuenza
vaccine: a Phase III, open-label study of adults in Brazil. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.10.003
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Fig. 1 – Hemagglutination-inhibition GMTs at Days 0 and 21 in the per-protocol immunogenicity cohort. GMT,  geometric
mean titer; CI, conﬁdence interval; adult, aged 18–60 years; older, aged >60 years.
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Fig. 2 – Summary of hemagglutination-inhibition seroconversion rates (A), seroprotection rates (B), and mean geometric
increase (C) in the per-protocol immunogenicity cohort. CI, conﬁdence interval; SPR, seroprotection rate; SCR,
seroconversion rate; MGI, mean geometric increase; European CHMP licensure criteria for immunogenicity deﬁned as at
least one criteria to be met  from: point estimate for SPR >70%, SCR >40% and MGI  >2.5 (adults aged 18–60 years) or SPR
>60%, SCR >30%, and MGI  >2.0 (older adults >60 years).21
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Table 2 – Solicited injection site adverse events and
general adverse events during the 4-day
post-vaccination period in the total vaccination cohort.
Adults Older adults
N = 62 N = 57
% (95% CI) % (95% CI)
Pain
All 43.5 (31.0, 56.7) 22.8 (12.7, 35.8)
Grade 3 4.8 (1.0, 13.5) 0
Redness
All 14.5 (6.9, 25.8) 12.3 (5.1, 23.7)
Grade 3 0.0 (0.0, 5.8) 0
Swelling
All 11.3 (4.7, 21.9) 10.5 (4.0, 21.5)
Grade 3 0.0 (0.0, 5.8) 0
Arthralgia
All 9.7 (3.6, 19.9) 3.5 (0.4, 12.1)
Grade 3 0 1.8 (0.0, 9.4)
Fatigue
All 9.7 (3.6, 19.9) 1.8 (0.0, 9.4)
Grade 3 1.6 (0.0, 8.7) 0
GI symptoms
All 4.8 (1.0, 13.5) 0
Grade 3 0 0
Headache
All 12.9 (5.7, 23.9) 1.8 (0.0, 9.4)
Grade 3 3.2 (0.4, 11.2) 1.8 (0.0, 9.4)
Myalgia
All 14.5 (6.9, 25.8) 3.5 (0.4, 12.1)
Grade 3 0 1.8 (0.0, 9.4)
Shivering
All 3.2 (0.4, 11.2) 0
Grade 3 1.6 (0.0, 8.7) 0
Sweating
All 3.2 (0.4, 11.2) 0
Grade 3 0 0
Fever
All 0 0
Grade 3 0 0
CI, conﬁdence interval; N, number of subjects in group; fever deﬁned
as ≥38.0 ◦C, Grade 3 >39.0 ◦C; adults, aged 18–60 years; older adults,b  r a z j i n f e c t d i s .
A summary of HI immunogenicity by vaccination history
s shown in Supplement 1. In adults who had received sea-
onal inﬂuenza vaccine in the preceding season, the baseline
eropositivity rate was 96.8–100% compared with 67.7–100%
n subjects who had not received the vaccine. In the older
dults who had received seasonal inﬂuenza vaccine in the pre-
eding season, the baseline seropositivity rate was 91.3–100%
ompared with 81.8–100% in those who  had not received the
accine. In adults and older adults who had received sea-
onal inﬂuenza vaccine in the preceding season, the vaccine
as immunogenic at Day 21, with SPRs of 100% and ≥93.5%,
espectively. The SCRs for the B/Yamagata strain were rela-
ively low in previously vaccinated adults and older adults
25.8% and 26.1%, respectively). In adults and older adults who
ad not received seasonal inﬂuenza vaccine in the preceding
eason, the vaccine was immunogenic at Day 21 against all
accine strains.
In adults who were seronegative at baseline, the SCR was
0–100% and in adults who  were seropositive at baseline,
he SCR was 47.5–76.9%. In older adults who were seroneg-
tive at baseline, the SCR for A/H1N1 and A/H3N2 was 90.0%
nd 79.0%, respectively. No older adult was seronegative for
nﬂuenza B strains at baseline. In older adults who were
eropositive at baseline, for A/H1N1 and A/H3N2, the SCR was
9.6% and 100%, respectively, and 35.1% for each inﬂuenza B
train.
eactogenicity
or 4-day post-vaccination, pain was the most common
olicited injection site AE in adults (43.5%; 27/62) and in older
dults (22.8%; 13/57). In adults, the rate of redness and swelling
as 14.5% (9/62) and 11.3% (7/62), respectively, and in older
dults, the rate of redness and swelling was 12.3% (7/57) and
0.5% (6/57), respectively. Grade 3 injection site AE pain was
eported by 4.8% of the adult group (Table 2).
For four days post-vaccination the most common solicited
eneral AEs in adults were myalgia (14.5%; 9/62) and headache
12.9%; 8/62), and there were two reports of Grade 3 headache
nd one report each of Grade 3 fatigue and shivering (Table 2).
n older adults the most common general AEs were myal-
ia and arthralgia (both 3.5%; 2/57). Grade 3 arthralgia,
eadache, and myalgia were reported by one older adult
Table 2).
afety
or 21 days post-vaccination, in the adults, the rate of unso-
icited AEs was 17.5% (11/63), including Grade 3 unsolicited
Es in four subjects which were pruritus (n = 1), urinary tract
nfection (n = 1), and sinusitis (n = 2). In older adults, the rate
f unsolicited AEs was 17.5% (10/57), including Grade 3 AEsPlease cite this article in press as: Zerbini CA, et al. Immunogenicity and
vaccine: a Phase III, open-label study of adults in Brazil. Braz J Infect Dis. 2
n two subjects which were upper respiratory tract infection
n = 1) and syncope (n = 1).
There was one SAE experienced by an 84-year old sub-
ect which was syncope, reported eight days post-vaccination,
hich resolved by the end of the study and which was not
onsidered by the investigator to be related to vaccination.aged >60 years.
Discussion
This Phase III, open-label study showed that IIV4 was
immunogenic and well-tolerated in adults (18–60 years) and
older adults (>60 years) in Brazil. HI antibody titers 21 days
after vaccination fulﬁlled European CHMP licensure criteria
for immunogenicity for each vaccine strain in each age group,
with SPRs of >98% in adults, and >94% in older adults. In
adults, the SCRs for all strains were >50%, and in older adults
were >60% for inﬂuenza A and >35% for inﬂuenza B. The base- safety of Southern Hemisphere inactivated quadrivalent inﬂuenza
016. http://dx.doi.org/10.1016/j.bjid.2016.10.003
line seropositivity rate (titer ≥1:10) was high (>80%) against
all strains in adults, and the entire older adult group were
seropositive for the B/Yamagata and B/Victoria strains and was
high with >90% for the inﬂuenza A strains. The safety proﬁle
ARTICLE IN PRESSBJID-665; No. of Pages 8
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was consistent with that observed for IIV4s from the same
manufacturer in previous Phase III studies in adults and older
adults.17,20
In Brazil, inﬂuenza vaccination is routinely available to
adults over 60 years of age and this was reﬂected in our
study by the rates of inﬂuenza vaccination in the preceding
two seasons in older adults (80.7%) compared with adults
(49.2%). However, baseline seropositivity rates were high in
both age groups, and the relatively high baseline seroposi-
tivity rates we  observed in adults, reﬂects that the vaccine
strains had been circulating during the previous season. In
both age groups, in subjects who  had received vaccine in the
preceding season, the vaccine was immunogenic with almost
all subjects achieving seroprotective HI titers (≥1:40). However,
among previously vaccinated subjects, the proportion achiev-
ing a four-fold increase in HI titer (SCR) was relatively low
(25–80%), particularly for the B/Yamagata strain at 25.8% in
adults and 26.1% in older adults.
High baseline antibody titers resulting from natural expo-
sure or previous vaccination are reported to reduce antibody
responses after seasonal inﬂuenza vaccination, such as in
older populations.23–28 When vaccine immunogenicity is
studied in populations that has high seropositivity pre-
vaccination, it may be difﬁcult to demonstrate an improved
immune response by looking at the SCR alone. To assess the
effect of baseline antibodies we could analyze SCRs accord-
ing to baseline seropositivity status. In our study, we showed
that in adults and older adults, SCRs were generally higher
against inﬂuenza A strains in subjects who  were seronega-
tive at baseline (80–100%) compared with subjects who were
seropositive (52.9–76.9%). In adults who were seronegative
for inﬂuenza B strains at baseline, the SCR against both
strains was 100%, compared with 47.5–59.3% in adults who
were seropositive at baseline. However, all older adults were
seropositive for both inﬂuenza B strains at baseline, and
SCRs for B/Yamagata and B/Victoria were both relatively low
at 35.1%. Although baseline antibody titers against vaccine
strains were higher and immune responses were lower in
older compared with younger adults, HI antibody responses
against all vaccine strains fulﬁlled licensure criteria in both
populations. These ﬁndings are consistent with observations
in Phase III randomized trials of Northern Hemisphere IIV4 in
adults and older adults, which showed that responses against
inﬂuenza B strains were lower in subjects who had received
IIV3 in the preceding three seasons than in subjects who
had not.17,20,25
During the development of IIV4s, it was hypothesized that
reactogenicity could be higher with the quadrivalent vaccine
that contained 60 g of HA than with the IIV3s, which con-
tained 45 g HA. Global Phase III studies showed that the
reactogenicity and safety proﬁles of IIV4s were consistent with
IIV3s, and the inclusion of an additional 15 g HA did not
appear to compromise safety.17,20 In a recent report from the
Vaccine Adverse Event Reporting System including reports for
IIV3s and IIV4s from July 2013 to March 2015, most of the
reported AEs were non-serious, and IIV3s and IIV4s had similar
29Please cite this article in press as: Zerbini CA, et al. Immunogenicity and
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safety proﬁles.
In our study, the solicited and unsolicited AE proﬁle sug-
gested that the vaccine was generally well tolerated. Solicited
AEs were more  frequent in adults than older adults, but 6;x x x(x x):xxx–xxx
Grade 3 AEs were infrequent (≤4.8% of all doses in adults
and ≤1.8% of all doses in older adults). No subjects with-
drew from the study for safety reasons and there was one
SAE (syncope eight days post-vaccination) experienced by an
84 year old subject which resolved by the end of the study
and was not considered by the investigator to be related to
vaccination.
A limitation of this study was that it included adults in
stable health including chronic conditions and the results
may not be generalizable to ‘highest-risk’ groups such as the
very frail, those with severe co-morbidities, obese people, and
post-partum women. A further limitation was that, although
HI antibody levels fulﬁlled the immunogenicity criteria used
by regulatory agencies to assess the suitability of seasonal
inﬂuenza vaccines, immunogenicity is a surrogate outcome
for clinical protection.
Because inﬂuenza B is less prone to antigenic shift than
inﬂuenza A, it is thought to be clinically less important than
inﬂuenza A infections. However, inﬂuenza B epidemics are
likely to be substantial since they occur in about half of
inﬂuenza seasons globally, including South America.6,9,30,31 In
an analysis of surveillance data in Brazil from 2000 to 2008,
inﬂuenza-like illness accounted for 4.39–16.9% of all hospital
consultations, and in 2008, 43.2% of conﬁrmed inﬂuenza cases
were inﬂuenza B.32 Based on the Global Inﬂuenza B Study, across
seasons from 2004 to 2012 in Brazil, the average inﬂuenza
A attack rate was higher (73.1%) than the rate of inﬂuenza
B (26.9%), which was consistent with inﬂuenza viral circula-
tion patterns globally.2 Moreover, the co-circulation of both
B lineages and vaccine mismatch with the inﬂuenza B lin-
eage in the recommended Southern Hemisphere IIV3 has been
observed in Brazil, including the 2013 season, when the rate of
B lineage mismatch with the lineage included in the vaccine
was 91.4%.3–7
Modeling studies suggest that switching from trivalent to
quadrivalent vaccines could reduce the number of medical
visits and hospitalizations, antibiotic prescriptions written for
inﬂuenza, and the economic impact of work absenteeism.
In a static model developed by the US Centers for Disease
Control and Prevention (CDC), the burden of inﬂuenza B was
estimated across 10 seasons, and switching from trivalent
to quadrivalent vaccines could have resulted in an annual
reduction of 1–321 per 100,000 inﬂuenza cases, and 0.06–2.7
per 100,000 fewer inﬂuenza-related hospitalizations depend-
ing upon the epidemic intensity of inﬂuenza B during each
season.8 The CDC model was adapted and used to assess the
cost of switching from trivalent to quadrivalent vaccines from
a Brazilian healthcare and societal perspective from 2010 to
2013.33 It was estimated that the use of quadrivalent instead
of trivalent vaccine in Brazil would have reduced the number
of inﬂuenza cases by 654,018, reduced the number of hospi-
talizations by 7536, and reduced inﬂuenza-related deaths by
1122. In 2013 when the rate of mismatch of IIV3 with the cir-
culating inﬂuenza B strain was >90%, the model showed that
quadrivalent vaccine could have avoided inﬂuenza-related
costs of R$ 1 million to the health system and R$ 62 million to
society.33 safety of Southern Hemisphere inactivated quadrivalent inﬂuenza
016. http://dx.doi.org/10.1016/j.bjid.2016.10.003
In summary, this Phase III, open-label study showed
that Southern Hemisphere IIV4 was immunogenic and well-
tolerated in adults from Brazil.
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